LumiraDx Announces FDA EUA Submission for its SARS-CoV-2 & F

/PRNewswire/ -- LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostic company, today announced it has submitted the LumiraDx SARS-CoV-2 & Flu A/B...

Related Keywords

United States , United Kingdom , London , City Of , Ron Zwanziger , Colleen Mcmillen , Exchange Commission , Department Of Health , Human Services , National Institutes Of Health , Drug Administration , National Institute Of Biomedical Imaging , Emergency Use Authorization , Lumiradx Point , Care Platform , Lumiradx Chief Executive Officer , Rapid Acceleration , National Institute , Biomedical Imaging , National Institutes , Securities Litigation Reform Act , Proxy Statement , Lumiradx Limited ,